Solventum completed the sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. for $4.0 billion in cash.
The net proceeds of $3.4 billion will primarily be used to pay down debt, accelerating Solventum's business transformation.
The updated full-year 2025 guidance includes organic sales growth, adjusted EPS range, and free cash flow expectations.
Sale Details
P&F business sold to Thermo Fisher for $4.0 billion in cash.
Debt Repayment
Net proceeds of $3.4 billion to be used primarily for debt repayment.
Guidance Update
Full-year 2025 guidance updated for organic sales growth, adjusted EPS range, and free cash flow expectations.
Financial Advisors
Morgan Stanley, Perella Weinberg Partners, and J.P. Morgan served as financial advisors to Solventum.
- The sale accelerates Solventum's business transformation and enhances flexibility for future investments.
- The updated guidance reflects improved financial metrics and strategic planning for the remainder of 2025.
Solventum's completion of the sale marks a significant milestone in its transformation plan, positioning the company for enhanced financial strength and strategic focus moving forward.